iBio to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company is known for its innovative FastPharming® Manufacturing System for biopharmaceuticals. A pre-recorded presentation will be available on demand for registered attendees starting May 24, 2022, and can also be accessed on iBio's website under 'News & Events'. iBio focuses on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases, leveraging its state-of-the-art manufacturing capabilities.

News Market Reaction – IBIO

-7.55%

-7.55% Session move

In the trading session that priced this news, IBIO declined 7.55%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming^® Manufacturing System, today announced that it will participate virtually in the H.C. Wainwright Global Investment Conference. The hybrid conference will take place May 23-26, 2022.

iBio's pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Tuesday, May 24, 2022, the presentation will also be available on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming^® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering^SM Development Services for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When is iBio participating in the H.C. Wainwright Global Investment Conference?

iBio will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022.

Where can I access iBio's presentation from the conference?

iBio's pre-recorded presentation will be available on demand for attendees starting May 24, 2022, and can also be accessed on their website.

What does iBio specialize in?

iBio specializes in next-generation biopharmaceuticals and sustainable, plant-based biologics manufacturing, particularly focusing on therapies for cancer, fibrotic, and infectious diseases.

What is the FastPharming Manufacturing System by iBio?

The FastPharming Manufacturing System is an innovative approach combining vertical farming and automated hydroponics to produce high-quality monoclonal antibodies and vaccines.

What is the ticker symbol for iBio?

The ticker symbol for iBio is IBIO.